Cartridge assemblies with absorbable metal staples and absorbable implantable adjuncts

Patent metadata

Field	Value
Publication number	US-12446874-B2
Application number	US-202217718879-A
Country	US
Kind code	B2
Filing date	Apr 12, 2022
Priority date	May 10, 2021
Publication date	Oct 21, 2025
Grant date	Oct 21, 2025

Abstract

A staple cartridge assembly includes a cartridge body with a deck, a longitudinal slot defined in the deck, and staple cavities defined in the deck. The staple cartridge assembly includes staples removably stored in the staple cavities, wherein the staples are deployable from the staple cavities into tissue of a patient, and wherein the staples comprise substrates comprised of metal that degrades when exposed to a degradation source in the patient. The staple cartridge assembly includes an implantable adjunct, wherein the staples are configured to hold the implantable adjunct to the tissue, and wherein the implantable adjunct is configured to delay an initiation of the degradation of regions of the metal in contact with the implantable adjunct in the patient, and wherein the implantable adjunct is configured to modify a local environment surrounding the staples to control a degradation rate of the staples after the initial delay.

First claim

What is claimed is:

1. A surgical staple cartridge assembly, comprising:
a cartridge body, comprising:
a deck;
a longitudinal slot defined in the deck; and
staple cavities defined in the deck; and

staples removably stored in the staple cavities, wherein the staples are deployable from the staple cavities into tissue of a patient, and wherein the staples comprise substrates comprised of metal that degrades when exposed to a degradation source in the patient, the staples comprising a first subset defining a first plurality of staples and a second subset defining a second plurality of staples; and
an implantable adjunct releasably secured to the deck and comprising a first portion and a second portion, wherein the staples are configured to hold the implantable adjunct to the tissue, wherein the first portion of the implantable adjunct is configured to delay an initiation of the degradation of regions of the first subset of staples at a first degradation rate, wherein the second portion of the implantable adjunct is configured to delay an initiation of the degradation of regions of the second subset of staples at a second degradation rate, different from the first degradation rate, wherein the first portion and the second portion are configured to chemically modify a local environment surrounding the staples to control the first and second degradation rates of the staples after the initial delay, and wherein the first portion and the second portion comprise at least one of a calcification inhibitor or a chelating agent, and the chemical modification is in response to a release of the at least one of the calcification inhibitor or the chelating agent from the implantable adjunct.

2. The surgical staple cartridge assembly of claim 1 , wherein the first and second portions are configured to delay the initiation of the degradation by physically shielding the regions of the metal from the degradation source.

3. The surgical staple cartridge assembly of claim 1 , wherein after the initial delay, the implantable adjunct is configured to reduce mineral deposition on the staples.

4. The surgical staple cartridge assembly of claim 1 , wherein the implantable adjunct comprises a bioabsorbable polymer.

5. The surgical staple cartridge assembly of claim 4 , wherein a degradation of the bioabsorbable polymer changes a pH of the local environment.

6. The staple surgical cartridge assembly of claim 1 , wherein the implantable adjunct preserves or increases the degradation rate of the staples after the initial delay.

7. The surgical staple cartridge assembly of claim 1 , wherein the first portion and the second portion of the implantable adjunct are coplanar.

8. The surgical staple cartridge assembly of claim 1 , wherein:
the first portion is configured to receive the first subset of staples;
the second portion is configured to receive the second subset of staples; and
the first portion and the second extend along a longitudinal axis of the implantable adjunct; and
the first portion is positioned medial to the second portion with respect to the longitudinal axis.

9. A surgical staple cartridge assembly, comprising:
a cartridge body, comprising:
a deck;
a longitudinal slot defined in the deck; and
staple cavities defined in the deck;

staples removably stored in the staple cavities, wherein the staples are deployable from the staple cavities into tissue of a patient, and wherein the staples comprise substrates comprised of metal that degrades when exposed to a degradation source in the patient; and
an implantable adjunct releasably secured to the deck, wherein the staples are configured to hold the implantable adjunct to the tissue, and wherein the implantable adjunct comprises:
a first portion configured to receive a first subset of the staples, wherein the first portion yields a first biocorrosion profile of the first subset of the staples in the patient; and
a second portion configured to receive a second subset of the staples, wherein the second portion yields a second biocorrosion profile of the second subset of the staples in the patient, and wherein the first biocorrosion profile is different than the second biocorrosion profile,

wherein the first biocorrosion profile causes a first degradation rate for the first subset of staples, and the second biocorrosion profile causes a second degradation rate for the second subset of staples, and
wherein the first portion and the second portion are configured to chemically modify a local environment surrounding the staples to control the first and second degradation rates of the staples after an initial delay.

10. The staple cartridge assembly of claim 9 , wherein the first subset of staples is proximal to the second subset of staples.

11. The staple cartridge assembly of claim 9 , wherein the first subset of staples defines a first row of staples, wherein the second subset of staples defines a second row of staples further away from the longitudinal slot than the first row of staples.

12. The staple cartridge assembly of claim 9 , wherein the first portion yields the first biocorrosion profile by causing a first initial delay in a biocorrosion of the first subset of the staples.

13. The staple cartridge assembly of claim 12 , wherein the first portion causes the first initial delay by physically shielding regions of the first subset of staples in contact with the first portion from a degradation source in the patient.

14. The staple cartridge assembly of claim 13 , wherein the second portion yields the second biocorrosion profile by causing a second initial delay in a biocorrosion of the second subset of the staples, wherein the second initial delay is different than the first initial delay.

15. The staple cartridge assembly of claim 14 , wherein the second portion causes the second initial delay by physically shielding regions of the second subset of staples in contact with the second portion from the degradation source in the patient.

16. The staple cartridge assembly of claim 15 , wherein after the first initial delay, the first portion is configured to reduce mineral deposition on the first subset of staples.

17. The surgical staple cartridge assembly of claim 9 , wherein the first portion and the second portion of the implantable adjunct are coplanar.

18. The surgical staple cartridge assembly of claim 9 , wherein the first portion and the second portion comprise at least one of a calcification inhibitor or a chelating agent, and the chemical modification is in response to a release of the at least one of the calcification inhibitor or the chelating agent from the implantable adjunct.

19. The surgical staple cartridge assembly of claim 9 , wherein:
the first portion and the second extend along a longitudinal axis of the implantable adjunct; and
the first portion is positioned medial to the second portion with respect to the longitudinal axis.

Assignees

• Cilag Gmbh Int

Inventors

• Shelton Iv Frederick E
• Harris Jason L
• Eckert Chad E

Classifications

• A61L2103/15

  Laboratory, medical or dentistry appliances, e.g. catheters or sharps · CPC title

• A61L2103/23

  Containers other than laboratory or medical, e.g. bottles or mail · CPC title

• A61L31/16

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title

• A61B2017/07264

  characterised by its staple forming cavities, e.g. geometry or material · CPC title

• A61B2017/00845

  of moving parts with respect to each other · CPC title